Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
View Top Employees from Protara Therapeutics| Website | http://www.protaratx.com |
| Revenue | $4 million |
| Employees | 31 (30 on RocketReach) |
| Founded | 2017 |
| Address | 345 Park Avenue South 3rd Floor, New York, New York 10010, US |
| Phone | (646) 817-2836 |
| Technologies |
JavaScript,
HTML,
PHP
+29 more
(view full list)
|
| Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Healthcare, Science and Engineering |
| SIC | SIC Code 80 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Protara Therapeutics employee's phone or email?
Protara Therapeutics Questions
The Protara Therapeutics annual revenue was $4 million in 2024.
Jesse Shefferman is the CEO of Protara Therapeutics.
30 people are employed at Protara Therapeutics.
Protara Therapeutics is based in New York, New York.
The NAICS codes for Protara Therapeutics are [3254, 32, 325].
The SIC codes for Protara Therapeutics are [80, 283, 28].
Top Protara Therapeutics Employees
-
55
-
15+
-
14
-
View
Wei Sun
Medical Director of Clinical Development at Protara Therapeutics
Fort Washington, PA, US32 -
15+
-
35
-
